{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:12:32Z","timestamp":1772208752693,"version":"3.50.1"},"reference-count":165,"publisher":"Bentham Science Publishers Ltd.","issue":"26","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Schizophrenia is a severe mental disorder that affects more than 1% of the population worldwide.\nDopamine system dysfunction and alterations in glutamatergic neurotransmission are strongly implicated\nin the aetiology of schizophrenia. To date, antipsychotic drugs are the only available treatment\nfor the symptoms of schizophrenia. These medications, which act as D2-receptor antagonist, adequately\naddress the positive symptoms of the disease, but they fail to improve the negative symptoms and cognitive\nimpairment. In schizophrenia, cognitive impairment is a core feature of the disorder. Therefore, the\ntreatment of cognitive impairment and the other symptoms related to schizophrenia remains a significant\nunmet medical need. Currently, phosphodiesterases (PDEs) are considered the best drug target for the\ntreatment of schizophrenia since many PDE subfamilies are abundant in the brain regions that are relevant\nto cognition. Thus, this review aims to illustrate the mechanism of PDEs in treating the symptoms\nof schizophrenia and summarises the encouraging results of PDE inhibitors as anti-schizophrenic drugs\nin preclinical and clinical studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200613202641","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T20:29:28Z","timestamp":1592080168000},"page":"2404-2421","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia"],"prefix":"10.2174","volume":"20","author":[{"given":"Mayasah Y.","family":"Al-Nema","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Gaurav","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.33160\/yam.2018.06.001","volume":"61","author":"Kaneko K.","year":"2018","unstructured":"Kaneko K.; Negative Symptoms and cognitive impairments in schizophrenia: two key symptoms negatively influencing social functioning. Yonago Acta Med 2018,61(2),91-102","journal-title":"Yonago Acta Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S1092852914000601","volume":"19","author":"Carbon M.","year":"2014","unstructured":"Carbon M.; Correll C.U.; Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 2014,19(Suppl. 1),38-52","journal-title":"CNS Spectr"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archpsyc.58.2.165","volume":"58","author":"Kirkpatrick B.","year":"2001","unstructured":"Kirkpatrick B.; Buchanan R.W.; Ross D.E.; Carpenter W.T.; Jr A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001,58(2),165-171","journal-title":"Arch Gen Psychiatry"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40501-016-0075-8","volume":"3","author":"Remington G.","year":"2016","unstructured":"Remington G.; Foussias G.; Fervaha G.; Agid O.; Takeuchi H.; Lee J.; Hahn M.; Treating negative symptoms in schizophrenia: An Update. Curr Treat Options Psychiatry 2016,3,133-150","journal-title":"Curr Treat Options Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","volume":"186","author":"Kirschner M.","year":"2017","unstructured":"Kirschner M.; Aleman A.; Kaiser S.; Secondary negative symptoms - A review of mechanisms, assessment and treatment. Schizophr Res 2017,186,29-38","journal-title":"Schizophr Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","volume":"71","author":"Bobes J.","year":"2010","unstructured":"Bobes J.; Arango C.; Garcia-Garcia M.; Rejas J.; Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry CLAMORS Study Collaborative Group2010,71(3),280-286","journal-title":"J Clin Psychiatry"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.psychres.2015.05.086","volume":"228","author":"Lyne J.","year":"2015","unstructured":"Lyne J.; Renwick L.; O\u2019Donoghue B.; Kinsella A.; Malone K.; Turner N.; O\u2019Callaghan E.; Clarke M.; Negative symptom domain prevalence across diagnostic boundaries: The relevance of diagnostic shifts. Psychiatry Res 2015,228(3),347-354","journal-title":"Psychiatry Res"},{"key":"ref=8","first-page":"44","author":"Bubl E.","year":"2018","unstructured":"Bubl E.; Werner L.; Liang Y.; Ebert D.; Friedel E.; Bubl A.; Bach M.; van Elst L.T.; Evaluating the neurobiological correlations and impact of treatment on cognitive dysfunction in ADHA and schizophrenia by means of the pattern electroretinogram. Schizophr Bull 2018,44","journal-title":"Schizophr Bull"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1152\/physrev.00004.2002","volume":"82","author":"Mattson M.P.","year":"2002","unstructured":"Mattson M.P.; Chan S.L.; Duan W.; Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol Rev 2002,82(3),637-672","journal-title":"Physiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","volume":"51","author":"Siuciak J.A.","year":"2006","unstructured":"Siuciak J.A.; Chapin D.S.; Harms J.F.; Lebel L.A.; McCarthy S.A.; Chambers L.; Shrikhande A.; Wong S.; Menniti F.S.; Schmidt C.J.; Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006,51(2),386-396","journal-title":"Neuropharmacology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2015.06.008","volume":"153","author":"Tsapakis E.M.","year":"2015","unstructured":"Tsapakis E.M.; Dimopoulou T.; Tarazi F.I.; Clinical management of negative symptoms of schizophrenia: An update. Pharmacol Ther 2015,153,135-147","journal-title":"Pharmacol Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/138161211795049624","volume":"17","author":"Kehler J.","year":"2011","unstructured":"Kehler J.; Nielsen J.; PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 2011,17(2),137-150","journal-title":"Curr Pharm Des"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"Howes O.D.","year":"2009","unstructured":"Howes O.D.; Kapur S.; The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009,35(3),549-562","journal-title":"Schizophr Bull"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1471-4159.2010.06604.x","volume":"113","author":"Perez-Costas E.","year":"2010","unstructured":"Perez-Costas E.; Melendez-Ferro M.; Roberts R.C.; Basal ganglia pathology in schizophrenia: dopamine connections and anomalies. J Neurochem 2010,113(2),287-302","journal-title":"J Neurochem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ajpath.2015.09.023","volume":"186","author":"Luo S.X.","year":"2016","unstructured":"Luo S.X.; Huang E.J.; Dopaminergic Neurons and Brain Reward Pathways: From Neurogenesis to Circuit Assembly. Am J Pathol 2016,186(3),478-488","journal-title":"Am J Pathol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","volume":"9","author":"Alexander G.E.","year":"1986","unstructured":"Alexander G.E.; DeLong M.R.; Strick P.L.; Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986,9,357-381","journal-title":"Annu Rev Neurosci"},{"key":"ref=17","doi-asserted-by":"publisher","author":"Alexander G.E.","unstructured":"Alexander G.E.; Crutcher M.D.; DeLong M.R.;  Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, \u201cprefrontal\u201d and \u201climbic\u201d functions. Prog. Brain Res., 1990, 85, 119-146.","DOI":"10.1016\/S0079-6123(08)62678-3"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","volume":"30","author":"Bj\u00f6rklund A.","year":"2007","unstructured":"Bj\u00f6rklund A.; Dunnett S.B.; Dopamine neuron systems in the brain: an update. Trends Neurosci 2007,30(5),194-202","journal-title":"Trends Neurosci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0006-8993(85)91524-0","volume":"327","author":"Graveland G.A.","year":"1985","unstructured":"Graveland G.A.; DiFiglia M.; The frequency and distribution of medium-sized neurons with indented nuclei in the primate and rodent neostriatum. Brain Res 1985,327(1-2),307-311","journal-title":"Brain Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/cne.903040406","volume":"304","author":"Hedreen J.C.","year":"1991","unstructured":"Hedreen J.C.; DeLong M.R.; Organization of striatopallidal, striatonigral, and nigrostriatal projections in the macaque. J Comp Neurol 1991,304(4),569-595","journal-title":"J Comp Neurol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0306-4522(97)00608-8","volume":"86","author":"Smith Y.","year":"1998","unstructured":"Smith Y.; Bevan M.D.; Shink E.; Bolam J.P.; Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998,86(2),353-387","journal-title":"Neuroscience"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(06)60001-0","author":"Tepper J.M.","unstructured":"Tepper J.M.; Abercrombie E.D.; Bolam J.P.;  Basal ganglia macrocircuits  Prog. Brain Res., 2007, 160, 3-7.","journal-title":"Basal ganglia macrocircuits"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev.ne.15.030192.001441","volume":"15","author":"Gerfen C.R.","year":"1992","unstructured":"Gerfen C.R.; The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992,15,285-320","journal-title":"Annu Rev Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0165-0173(94)00007-C","volume":"20","author":"Parent A.","year":"1995","unstructured":"Parent A.; Hazrati L.N.; Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995,20(1),91-127","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1523\/JNEUROSCI.11-04-01016.1991","volume":"11","author":"Gerfen C.R.","year":"1991","unstructured":"Gerfen C.R.; McGinty J.F.; Young W.S.; III Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991,11(4),1016-1031","journal-title":"J Neurosci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S1471-1931(00)00019-7","volume":"23","author":"Gerfen C.R.","year":"2000","unstructured":"Gerfen C.R.; Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci 2000,23(10)(Suppl.),S64-S70","journal-title":"Trends Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"8498","DOI":"10.1523\/JNEUROSCI.17-21-08498.1997","volume":"17","author":"Abercrombie E.D.","year":"1997","unstructured":"Abercrombie E.D.; DeBoer P.; Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J Neurosci 1997,17(21),8498-8505","journal-title":"J Neurosci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nature09159","volume":"466","author":"Kravitz A.V.","year":"2010","unstructured":"Kravitz A.V.; Freeze B.S.; Parker P.R.; Kay K.; Thwin M.T.; Deisseroth K.; Kreitzer A.C.; Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010,466(7306),622-626","journal-title":"Nature"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/nn.3743","volume":"17","author":"Calabresi P.","year":"2014","unstructured":"Calabresi P.; Picconi B.; Tozzi A.; Ghiglieri V.; Di Filippo M.; Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 2014,17(8),1022-1030","journal-title":"Nat Neurosci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"Jentsch J.D.","year":"1999","unstructured":"Jentsch J.D.; Roth R.H.; The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999,20(3),201-225","journal-title":"Neuropsychopharmacology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0006-2952(91)90004-O","volume":"41","author":"Huettner J.E.","year":"1991","unstructured":"Huettner J.E.; Competitive antagonism of glycine at the N-methyl-D-aspartate (NMDA) receptor. Biochem Pharmacol 1991,41(1),9-16","journal-title":"Biochem Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0301-0082(00)00044-7","volume":"64","author":"Prast H.","year":"2001","unstructured":"Prast H.; Philippu A.; Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001,64(1),51-68","journal-title":"Prog Neurobiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbr.2014.06.008","volume":"285","author":"Pitsikas N.","year":"2015","unstructured":"Pitsikas N.; The role of nitric oxide in the object recognition memory. Behav Brain Res 2015,285,200-207","journal-title":"Behav Brain Res"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.5772\/67267","author":"Dagdeviren M.","year":"2017","unstructured":"Dagdeviren M.;  Role of nitric oxide synthase in normal brain function and pathophysiology of neural diseases Nitric Oxide Synthase: Simple Enzyme-Complex Roles 2017","journal-title":"Role of nitric oxide synthase in normal brain function and pathophysiology of neural diseases Nitric Oxide Synthase: Simple Enzyme-Complex Roles"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/nbdi.1997.0153","volume":"4","author":"Coyle J.T.","year":"1997","unstructured":"Coyle J.T.; The nagging question of the function of N-acetylaspartylglutamate. Neurobiol Dis 1997,4(3-4),231-238","journal-title":"Neurobiol Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0304-3940(80)90178-0","volume":"20","author":"Kim J.S.","year":"1980","unstructured":"Kim J.S.; Kornhuber H.H.; Schmid-Burgk W.; Holzm\u00fcller B.; Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980,20(3),379-382","journal-title":"Neurosci Lett"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuropharm.2015.10.037","volume":"102","author":"Li Y-W.","year":"2016","unstructured":"Li Y-W.; Seager M.A.; Wojcik T.; Heman K.; Molski T.F.; Fernandes A.; Langdon S.; Pendri A.; Gerritz S.; Tian Y.; Hong Y.; Gallagher L.; Merritt J.R.; Zhang C.; Westphal R.; Zaczek R.; Macor J.E.; Bronson J.J.; Lodge N.J.; Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy. Neuropharmacology 2016,102,121-135","journal-title":"Neuropharmacology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/odi.12275","volume":"21","author":"Ahmad F.","year":"2015","unstructured":"Ahmad F.; Murata T.; Simizu K.; Degeman E.; Maurice D.; Manganiello V.; Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets. Oral disease. PMC 2015,21(1),25-50","journal-title":"PMC"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.02.009","author":"Tsai E. J.","unstructured":"Tsai E. J.; Kass D. A.;  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics  Pharmacol therapeut, 2009, 122(3), 216-38","journal-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","volume":"91","author":"Francis S.H.","year":"2011","unstructured":"Francis S.H.; Blount M.A.; Corbin J.D.; Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011,91(2),651-690","journal-title":"Physiol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"Maurice D.H.","year":"2014","unstructured":"Maurice D.H.; Ke H.; Ahmad F.; Wang Y.; Chung J.; Manganiello V.C.; Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014,13(4),290-314","journal-title":"Nat Rev Drug Discov"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"Bender A.T.","year":"2006","unstructured":"Bender A.T.; Beavo J.A.; Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006,58(3),488-520","journal-title":"Pharmacol Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/bph.12168","volume":"196","author":"Eschenhagen T.","year":"2013","unstructured":"Eschenhagen T.; PDE4 in the human heart-major player or littel helper? BJP 2013,196(3),524-527","journal-title":"BJP"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4137\/CCRPM.S7211","volume":"7","author":"Ejiofor S.","year":"2013","unstructured":"Ejiofor S.; Turner A.M.; Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med 2013,7,17-34","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11884-013-0184-9","volume":"8","author":"Gacci M.","year":"2013","unstructured":"Gacci M.; Sebastianelli A.; Salvi M.; Vignozzi L.; Corona G.; McVary K.T.; Kaplan S.A.; Oelke M.; Maggi M.; Carini M.; PED5-Is for the Treatment of concomitant ED and LUTS\/BPH. Curr Bladder Dysfunct Rep 2013,8(2),150-159","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","volume":"76","author":"Conti M.","year":"2007","unstructured":"Conti M.; Beavo J.; Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007,76,481-511","journal-title":"Annu Rev Biochem"},{"key":"ref=47","first-page":"54","volume":"8","author":"Menniti F.S.","year":"2007","unstructured":"Menniti F.S.; Chappie T.A.; Humphrey J.M.; Schmidt C.J.; Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007,8(1),54-59","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1124\/jpet.109.155994","volume":"331","author":"Grauer S.M.","year":"2009","unstructured":"Grauer S.M.; Pulito V.L.; Navarra R.L.; Kelly M.P.; Kelley C.; Graf R.; Langen B.; Logue S.; Brennan J.; Jiang L.; Charych E.; Egerland U.; Liu F.; Marquis K.L.; Malamas M.; Hage T.; Comery T.A.; Brandon N.J.; Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 2009,331(2),574-590","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.coph.2011.09.002","volume":"11","author":"Chan S.","year":"2011","unstructured":"Chan S.; Yan C.; PDE1 isozymes, key regulators of pathological vascular remodeling. Curr Opin Pharmacol 2011,11(6),720-724","journal-title":"Curr Opin Pharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","volume":"233","author":"Snyder G.L.","year":"2016","unstructured":"Snyder G.L.; Prickaerts J.; Wadenberg M.L.; Zhang L.; Zheng H.; Yao W.; Akkerman S.; Zhu H.; Hendrick J.P.; Vanover K.E.; Davis R.; Li P.; Mates S.; Wennogle L.P.; Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats. Psychopharmacology (Berl) 2016,233(17),3113-3124","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"Boess F.G.","year":"2004","unstructured":"Boess F.G.; Hendrix M.; van der Staay F-J.; Erb C.; Schreiber R.; van Staveren W.; de Vente J.; Prickaerts J.; Blokland A.; Koenig G.; Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004,47(7),1081-1092","journal-title":"Neuropharmacology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1124\/jpet.109.156729","volume":"331","author":"Masood A.","year":"2009","unstructured":"Masood A.; Huang Y.; Hajjhussein H.; Xiao L.; Li H.; Wang W.; Hamza A.; Zhan C-G.; O\u2019Donnell J.M.; Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 2009,331(2),690-699","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1071-9164(03)00135-0","volume":"9","author":"Movsesian M.A.","year":"2003","unstructured":"Movsesian M.A.; PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail 2003,9(6),475-480","journal-title":"J Card Fail"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2170\/jjphysiol.52.471","volume":"52","author":"Yashiro Y.","year":"2002","unstructured":"Yashiro Y.; Ohhashi T.; Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. Jpn J Physiol 2002,52(5),471-477","journal-title":"Jpn J Physiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","volume":"163","author":"Rabe K.F.","year":"2011","unstructured":"Rabe K.F.; Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011,163(1),53-67","journal-title":"Br J Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/2319-4170.106152","volume":"35","author":"Jin S.L.","year":"2012","unstructured":"Jin S.L.; Ding S.L.; Lin S.C.; Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J 2012,35(3),197-210","journal-title":"Chang Gung Med J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MOU.0b013e328333ac68","volume":"20","author":"Wang C.","year":"2010","unstructured":"Wang C.; Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010,20(1),49-54","journal-title":"Curr Opin Urol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/17460441.2013.787986","volume":"8","author":"Safavi M.","year":"2013","unstructured":"Safavi M.; Baeeri M.; Abdollahi M.; New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders. Expert Opin Drug Discov 2013,8(6),733-751","journal-title":"Expert Opin Drug Discov"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"19532","DOI":"10.1073\/pnas.0806152105","volume":"105","author":"Zhang L.","year":"2008","unstructured":"Zhang L.; Murray F.; Zahno A.; Kanter J.R.; Chou D.; Suda R.; Fenlon M.; Rassenti L.; Cottam H.; Kipps T.J.; Insel P.A.; Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2008,105(49),19532-19537","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1124\/mol.110.069104","volume":"79","author":"Tsai L-C.L.","year":"2011","unstructured":"Tsai L-C.L.; Shimizu-Albergine M.; Beavo J.A.; The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol 2011,79(4),639-648","journal-title":"Mol Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"Reneerkens O.A.","year":"2009","unstructured":"Reneerkens O.A.; Rutten K.; Steinbusch H.W.; Blokland A.; Prickaerts J.; Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009,202(1-3),419-443","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.neuroscience.2016.10.006","volume":"339","author":"Tomimatsu Y.","year":"2016","unstructured":"Tomimatsu Y.; Cash D.; Suzuki M.; Suzuki K.; Bernanos M.; Simmons C.; Williams S.C.R.; Kimura H.; TAK-063, a phosphodiesterase 10A inhibitor, modulates neuronal activity in various brain regions in phMRI and EEG studies with and without ketamine challenge. Neuroscience 2016,339,180-190","journal-title":"Neuroscience"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"Lakics V.","year":"2010","unstructured":"Lakics V.; Karran E.H.; Boess F.G.; Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010,59(6),367-374","journal-title":"Neuropharmacology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd2058","volume":"5","author":"Menniti F.S.","year":"2006","unstructured":"Menniti F.S.; Faraci W.S.; Schmidt C.J.; Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006,5(8),660-670","journal-title":"Nat Rev Drug Discov"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnana.2011.00043","volume":"5","author":"Nishi A.","year":"2011","unstructured":"Nishi A.; Kuroiwa M.; Shuto T.; Mechanisms for the modulation of dopamine d(1) receptor signaling in striatal neurons. Front Neuroanat 2011,5,43","journal-title":"Front Neuroanat"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.10R01FM","volume":"114","author":"Nishi A.","year":"2010","unstructured":"Nishi A.; Snyder G.L.; Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Pharmacol Sci 2010,114(1),6-16","journal-title":"J Pharmacol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ijnp\/pyw030","volume":"19","author":"Heckman P.R.A.","year":"2016","unstructured":"Heckman P.R.A.; van Duinen M.A.; Bollen E.P.P.; Nishi A.; Wennogle L.P.; Blokland A.; Prickaerts J.; Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications. Int J Neuropsychopharmacol 2016,19(10),30","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-319-58811-7_9","author":"Dorner-Ciossek C.","year":"2017","unstructured":"Dorner-Ciossek C.; Kroker K.; Rosenbrock H.;  Phosphodiesterase: CNS Functions and Diseases 2017,231-254","journal-title":"Phosphodiesterase: CNS Functions and Diseases"},{"key":"ref=69","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-16-S1-A19","volume":"16","author":"Rosenbrock H.","year":"2015","unstructured":"Rosenbrock H.; Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement. BMC Pharmacol Toxicol 2015,16(S1)","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1124\/jpet.117.245506","volume":"365","author":"Nakashima M.","year":"2018","unstructured":"Nakashima M.; Imada H.; Shiraishi E.; Ito Y.; Suzuki N.; Miyamoto M.; Taniguchi T.; Iwashita H.; Phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-methyl-D-aspartate receptor antagonist\u2013induced rat models of schizophrenia. J Pharmacol Exp Ther 2018,365(1),179-188","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1523\/JNEUROSCI.19-16-06784.1999","volume":"19","author":"Ko G.Y.","year":"1999","unstructured":"Ko G.Y.; Kelly P.T.; Nitric oxide acts as a postsynaptic signaling molecule in calcium\/calmodulin-induced synaptic potentiation in hippocampal CA1 pyramidal neurons. J Neurosci 1999,19(16),6784-6794","journal-title":"J Neurosci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"10250","DOI":"10.1523\/JNEUROSCI.19-23-10250.1999","volume":"19","author":"Lu Y-F.","year":"1999","unstructured":"Lu Y-F.; Kandel E.R.; Hawkins R.D.; Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 1999,19(23),10250-10261","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.euroneuro.2011.12.008","volume":"22","author":"Liemburg E.J.","year":"2012","unstructured":"Liemburg E.J.; Knegtering H.; Klein H.C.; Kortekaas R.; Aleman A.; Antipsychotic medication and prefrontal cortex activation: a review of neuroimaging findings. Eur Neuropsychopharmacol 2012,22(6),387-400","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1093\/cercor\/bht195","volume":"23","author":"Arnsten A.F.","year":"2013","unstructured":"Arnsten A.F.; The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937-2003. Cereb Cortex 2013,23(10),2269-2281","journal-title":"Cereb Cortex"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1055\/s-2006-931498","volume":"39","author":"Winterer G.","year":"2006","unstructured":"Winterer G.; Cortical microcircuits in schizophrenia--the dopamine hypothesis revisited. Pharmacopsychiatry 2006,39(Suppl. 1),S68-S71","journal-title":"Pharmacopsychiatry"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.tins.2004.08.002","volume":"27","author":"Winterer G.","year":"2004","unstructured":"Winterer G.; Weinberger D.R.; Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004,27(11),683-690","journal-title":"Trends Neurosci"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/BF03189702","volume":"10","author":"Vereczkey L.","year":"1985","unstructured":"Vereczkey L.; Pharmacokinetics and metabolism of vincamine and related compounds. Eur J Drug Metab Pharmacokinet 1985,10(2),89-103","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF02244119","volume":"101","author":"Nicholson C.D.","year":"1990","unstructured":"Nicholson C.D.; Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl) 1990,101(2),147-159","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0014-2999(92)90602-Z","volume":"215","author":"Moln\u00e1r P.","year":"1992","unstructured":"Moln\u00e1r P.; Ga\u00e1l L.; Effect of different subtypes of cognition enhancers on long-term potentiation in the rat dentate gyrus in vivo. Eur J Pharmacol 1992,215(1),17-22","journal-title":"Eur J Pharmacol"},{"key":"ref=80","first-page":"255","volume":"2","author":"Moln\u00e1r P.","year":"1994","unstructured":"Moln\u00e1r P.; Ga\u00e1l L.; Horv\u00e1th C.; The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers. Neurobiology (Bp) 1994,2(3),255-266","journal-title":"Neurobiology (Bp)"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0361-9230(02)00873-0","volume":"59","author":"Lendvai B.","year":"2003","unstructured":"Lendvai B.; Zelles T.; Rozsa B.; Vizi E.S.; A vinca alkaloid enhances morphological dynamics of dendritic spines of neocortical layer 2\/3 pyramidal cells. Brain Res Bull 2003,59(4),257-260","journal-title":"Brain Res Bull"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0091-3057(87)90552-1","volume":"26","author":"DeNoble V.J.","year":"1987","unstructured":"DeNoble V.J.; Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Pharmacol Biochem Behav 1987,26(1),183-186","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00004850-199100610-00005","volume":"6","author":"Hindmarch I.","year":"1991","unstructured":"Hindmarch I.; Fuchs H.H.; Erzigkeit H.; Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 1991,6(1),31-43","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0731-7085(85)80016-9","volume":"3","author":"Polg\u00e1r M.","year":"1985","unstructured":"Polg\u00e1r M.; Vereczkey L.; Ny\u00e1ry I.; Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion. J Pharm Biomed Anal 1985,3(2),131-139","journal-title":"J Pharm Biomed Anal"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1021\/acs.jmedchem.5b01751","volume":"59","author":"Li P.","year":"2016","unstructured":"Li P.; Zheng H.; Zhao J.; Zhang L.; Yao W.; Zhu H.; Beard J.D.; Ida K.; Lane W.; Snell G.; Sogabe S.; Heyser C.J.; Snyder G.L.; Hendrick J.P.; Vanover K.E.; Davis R.E.; Wennogle L.P.; Discovery of potent and selective inhibitors of phosphodiesterase 1 for the treatment of cognitive impairment associated with neurodegenerative and neuropsychiatric diseases. J Med Chem 2016,59(3),1149-1164","journal-title":"J Med Chem"},{"key":"ref=86","unstructured":"Clinical trial study found in clinical trials for ITI-214:\n NCT01900522. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01900522\n  (Accessed October 30, 2019)  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01900522"},{"key":"ref=87","unstructured":"Clinical trial study found in clinical trials for ITI-214:\n  NCT03489772   xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03489772 (Accessed October 30, 2019)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1021\/acs.jmedchem.7b00302","volume":"60","author":"Dyck B.","year":"2017","unstructured":"Dyck B.; Branstetter B.; Gharbaoui T.; Hudson A.R.; Breitenbucher J.G.; Gomez L.; Botrous I.; Marrone T.; Barido R.; Allerston C.K.; Cedervall E.P.; Xu R.; Sridhar V.; Barker R.; Aertgeerts K.; Schmelzer K.; Neul D.; Lee D.; Massari M.E.; Andersen C.B.; Sebring K.; Zhou X.; Petroski R.; Limberis J.; Augustin M.; Chun L.E.; Edwards T.E.; Peters M.; Tabatabaei A.; Discovery of selective phosphodiesterase 1 inhibitors with memory enhancing properties. J Med Chem 2017,60(8),3472-3483","journal-title":"J Med Chem"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1369\/jhc.2009.953471","volume":"57","author":"Stephenson D.T.","year":"2009","unstructured":"Stephenson D.T.; Coskran T.M.; Wilhelms M.B.; Adamowicz W.O.; O\u2019Donnell M.M.; Muravnick K.B.; Menniti F.S.; Kleiman R.J.; Morton D.; Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem 2009,57(10),933-949","journal-title":"J Histochem Cytochem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","volume":"226","author":"Stephenson D.T.","year":"2012","unstructured":"Stephenson D.T.; Coskran T.M.; Kelly M.P.; Kleiman R.J.; Morton D.; O\u2019Neill S.M.; Schmidt C.J.; Weinberg R.J.; Menniti F.S.; The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 2012,226,145-155","journal-title":"Neuroscience"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1021\/acsmedchemlett.6b00514","volume":"8","author":"Abdel-Magid A.F.","year":"2016","unstructured":"Abdel-Magid A.F.; Potential treatment of cognitive impairment in schizophrenia by phosphodiesterase 2 (PDE2) inhibitors. ACS Med Chem Lett 2016,8(1),17-18","journal-title":"ACS Med Chem Lett"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1021\/acs.jmedchem.7b01370","volume":"61","author":"Wu Y.","year":"2018","unstructured":"Wu Y.; Li Z.; Huang Y-Y.; Wu D.; Luo H-B.; Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer\u2019s Disease. J Med Chem 2018,61(13),5467-5483","journal-title":"J Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","volume":"558","author":"Rutten K.","year":"2007","unstructured":"Rutten K.; Prickaerts J.; Hendrix M.; van der Staay F.J.; \u015eik A.; Blokland A.; Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007,558(1-3),107-112","journal-title":"Eur J Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2008.02.108","volume":"1216","author":"Domek-\u0141opaci\u0144ska K.","year":"2008","unstructured":"Domek-\u0141opaci\u0144ska K.; Strosznajder J.B.; The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008,1216,68-77","journal-title":"Brain Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","volume":"236","author":"Reneerkens O.A.H.","year":"2013","unstructured":"Reneerkens O.A.H.; Rutten K.; Bollen E.; Hage T.; Blokland A.; Steinbusch H.W.M.; Prickaerts J.; Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 2013,236(1),16-22","journal-title":"Behav Brain Res"},{"key":"ref=96","doi-asserted-by":"publisher","author":"Snyder G.L.","unstructured":"Snyder G.L.; Vanover K.E.;  Phosphodiesterases: CNS Functions and Diseases Zhang, H.T.; Xu, Y.; O\u2019Donnell, J.M., Eds.; Springer: Berlin, 2017,\n  pp. 385-409.","DOI":"10.1007\/978-3-319-58811-7_14"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/syn.21840","volume":"69","author":"Fern\u00e1ndez-Fern\u00e1ndez D.","year":"2015","unstructured":"Fern\u00e1ndez-Fern\u00e1ndez D.; Rosenbrock H.; Kroker K.S.; Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus. Synapse 2015,69(10),484-496","journal-title":"Synapse"},{"key":"ref=98","unstructured":"Clinical trial study found in clinical trials for PF-05180999:\n NCT01429740  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01429740 (Accessed February 5, 2020)"},{"key":"ref=99","unstructured":"Clinical trial study found in clinical trials for PF-05180999:\n NCT01530529 xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01530529 (Accessed February 5, 2020)"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1021\/acs.jmedchem.7b00397","volume":"60","author":"Helal C.J.","year":"2017","unstructured":"Helal C.J.; Arnold E.P.; Boyden T.L.; Chang C.; Chappie T.A.; Fennell K.F.; Forman M.D.; Hajos M.; Harms J.F.; Hoffman W.E.; Humphrey J.M.; Kang Z.; Kleiman R.J.; Kormos B.L.; Lee C.W.; Lu J.; Maklad N.; McDowell L.; Mente S.; O\u2019Connor R.E.; Pandit J.; Piotrowski M.; Schmidt A.W.; Schmidt C.J.; Ueno H.; Verhoest P.R.; Yang E.X.; Application of structure-based design and parallel chemistry to identify a potent, selective, and brain penetrant Phosphodiesterase 2A inhibitor. J Med Chem 2017,60(13),5673-5698","journal-title":"J Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1016\/j.bmcl.2013.10.014","volume":"23","author":"Gomez L.","year":"2013","unstructured":"Gomez L.; Breitenbucher J.G.; PDE2 inhibition: potential for the treatment of cognitive disorders. Bioorg Med Chem Lett 2013,23(24),6522-6527","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=102","unstructured":"Clinical trial study found in clinical trials for TAK-915:\n NCT0258456   xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02584569 (Accessed February 5, 2020)"},{"key":"ref=103","unstructured":"Clinical trial study found in clinical trials for TAK-915:\n NCT02461160  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02461160 (Accessed February 5, 2020)"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1517\/14728222.2013.818656","volume":"17","author":"Richter W.","year":"2013","unstructured":"Richter W.; Menniti F.S.; Zhang H.T.; Conti M.; PDE4 as a target for cognition enhancement. Expert Opin Ther Targets 2013,17(9),1011-1027","journal-title":"Expert Opin Ther Targets"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/(SICI)1096-9861(19990503)407:2<287:AID-CNE9>3.0.CO;2-R","volume":"407","author":"Cherry J.A.","year":"1999","unstructured":"Cherry J.A.; Davis R.L.; Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J Comp Neurol 1999,407(2),287-301","journal-title":"J Comp Neurol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrn1406","volume":"5","author":"Wise R.A.","year":"2004","unstructured":"Wise R.A.; Dopamine, learning and motivation. Nat Rev Neurosci 2004,5(6),483-494","journal-title":"Nat Rev Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/npp.2015.240","volume":"41","author":"McGirr A.","year":"2016","unstructured":"McGirr A.; Lipina T.V.; Mun H.S.; Georgiou J.; Al-Amri A.H.; Ng E.; Zhai D.; Elliott C.; Cameron R.T.; Mullins J.G.; Liu F.; Baillie G.S.; Clapcote S.J.; Roder J.C.; Specific inhibition of phosphodiesterase-4B results in anxiolysis and facilitates memory acquisition. Neuropsychopharmacology 2016,41(4),1080-1092","journal-title":"Neuropsychopharmacology"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00213-011-2436-8","volume":"219","author":"Kuroiwa M.","year":"2012","unstructured":"Kuroiwa M.; Snyder G.L.; Shuto T.; Fukuda A.; Yanagawa Y.; Benavides D.R.; Nairn A.C.; Bibb J.A.; Greengard P.; Nishi A.; Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor\/PKA\/DARPP-32 signaling cascade in frontal cortex. Psychopharmacology (Berl) 2012,219(4),1065-1079","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1037\/0894-4105.12.3.426","volume":"12","author":"Heinrichs R.W.","year":"1998","unstructured":"Heinrichs R.W.; Zakzanis K.K.; Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998,12(3),426-445","journal-title":"Neuropsychology"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","volume":"174","author":"Goldman-Rakic P.S.","year":"2004","unstructured":"Goldman-Rakic P.S.; Castner S.A.; Svensson T.H.; Siever L.J.; Williams G.V.; Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004,174(1),3-16","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"RC23","DOI":"10.1523\/JNEUROSCI.19-18-j0001.1999","volume":"19","author":"Taylor J.R.","year":"1999","unstructured":"Taylor J.R.; Birnbaum S.; Ubriani R.; Arnsten A.F.; Activation of cAMP-dependent protein kinase A in prefrontal cortex impairs working memory performance. J Neurosci 1999,19(18),RC23","journal-title":"J Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"Burgin A.B.","year":"2010","unstructured":"Burgin A.B.; Magnusson O.T.; Singh J.; Witte P.; Staker B.L.; Bjornsson J.M.; Thorsteinsdottir M.; Hrafnsdottir S.; Hagen T.; Kiselyov A.S.; Stewart L.J.; Gurney M.E.; Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010,28(1),63-70","journal-title":"Nat Biotechnol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/j.1476-5381.2011.01524.x","volume":"164","author":"Bruno O.","year":"2011","unstructured":"Bruno O.; Fedele E.; Prickaerts J.; Parker L.A.; Canepa E.; Brullo C.; Cavallero A.; Gardella E.; Balbi A.; Domenicotti C.; Bollen E.; Gijselaers H.J.; Vanmierlo T.; Erb K.; Limebeer C.L.; Argellati F.; Marinari U.M.; Pronzato M.A.; Ricciarelli R.; GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 2011,164(8),2054-2063","journal-title":"Br J Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s002130000414","volume":"150","author":"Zhang H.T.","year":"2000","unstructured":"Zhang H.T.; O\u2019Donnell J.M.; Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berl) 2000,150(3),311-316","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/00498258809041693","volume":"18","author":"Krause W.","year":"1988","unstructured":"Krause W.; K\u00fchne G.; Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 1988,18(5),561-571","journal-title":"Xenobiotica"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchemneu.2010.03.004","volume":"40","author":"Mori F.","year":"2010","unstructured":"Mori F.; P\u00e9rez-Torres S.; De Caro R.; Porzionato A.; Macchi V.; Beleta J.; Gavald\u00e0 A.; Palacios J.M.; Mengod G.; The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 2010,40(1),36-42","journal-title":"J Chem Neuroanat"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbr.2016.01.031","volume":"303","author":"Vanmierlo T.","year":"2016","unstructured":"Vanmierlo T.; Creemers P.; Akkerman S.; van Duinen M.; Sambeth A.; De Vry J.; Uz T.; Blokland A.; Prickaerts J.; The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav Brain Res 2016,303,26-33","journal-title":"Behav Brain Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neuropharm.2017.12.019","volume":"131","author":"Van Duinen M.A.","year":"2018","unstructured":"Van Duinen M.A.; Sambeth A.; Heckman P.R.A.; Smit S.; Tsai M.; Lahu G.; Uz T.; Blokland A.; Prickaerts J.; Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology 2018,131,31-38","journal-title":"Neuropharmacology"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"S1024","DOI":"10.1016\/S0924-977X(17)31794-7","volume":"27","author":"Van Duinen M.A.","year":"2017","unstructured":"Van Duinen M.A.; Heckman P.R.A.; Vanmierlo T.; Sambeth A.; Ogrinc F.; Tsai M.; Lahu G.; Uz T.; Blokland A.; Prickaerts J.; The PDE4-inhbitor roflumilast improves episodic memory: findings from a translational perspective. Eur Neuropsychopharmacol 2017,27,S1024-S1025","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=120","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5134-y","author":"Gilleen J.","unstructured":"Gilleen J.; Farah Y.; Davison C.; Kerins S.; Valdearenas L.; Uz T.; Lahu G.; Tsai M.; Ogrinc F.; Reichenberg A.; Williams S.C.; Mehta M.A.; Shergill S.S.;  An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients Psychopharmacology (Berl), 2018 (ePub ahead of print)","journal-title":"An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients Psychopharmacology (Berl), 2018 (ePub ahead of print)"},{"key":"ref=121","unstructured":"Clinical trial study found in clinical trials for Roflumilast:\nNCT01433666  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01433666 (Accessed November 4, 2019)"},{"key":"ref=122","unstructured":"Clinical trial study found in clinical trials for HT-0712:\n  NCT02013310  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02013310 (Accessed November 4, 2019)"},{"key":"ref=123","unstructured":"Clinical trial study found in clinical trials for BPN14770:\n NCT03030105   xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03030105 (Accessed November 1, 2019)"},{"key":"ref=124","unstructured":"Clinical trial study found in clinical trials for Etazolate:\n  NCT00880412  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00880412 (Accessed November 4, 2019)"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","volume":"273","author":"Fisher D.A.","year":"1998","unstructured":"Fisher D.A.; Smith J.F.; Pillar J.S.; St Denis S.H.; Cheng J.B.; Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998,273(25),15559-15564","journal-title":"J Biol Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"15553","DOI":"10.1074\/jbc.273.25.15553","volume":"273","author":"Soderling S.H.","year":"1998","unstructured":"Soderling S.H.; Bayuga S.J.; Beavo J.A.; Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998,273(25),15553-15558","journal-title":"J Biol Chem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"9068","DOI":"10.1523\/JNEUROSCI.21-22-09068.2001","volume":"21","author":"Andreeva S.G.","year":"2001","unstructured":"Andreeva S.G.; Dikkes P.; Epstein P.M.; Rosenberg P.A.; Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain. J Neurosci 2001,21(22),9068-9076","journal-title":"J Neurosci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuropharm.2008.07.005","volume":"55","author":"van der Staay F.J.","year":"2008","unstructured":"van der Staay F.J.; Rutten K.; B\u00e4rfacker L.; Devry J.; Erb C.; Heckroth H.; Karthaus D.; Tersteegen A.; van Kampen M.; Blokland A.; Prickaerts J.; Reymann K.G.; Schr\u00f6der U.H.; Hendrix M.; The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008,55(5),908-918","journal-title":"Neuropharmacology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.brainres.2016.04.011","volume":"1642","author":"Li J.","year":"2016","unstructured":"Li J.; Liu C-N.; Wei N.; Li X-D.; Liu Y-Y.; Yang R.; Jia Y-J.; Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-\u03b2 peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer\u2019s disease. Brain Res 2016,1642,327-335","journal-title":"Brain Res"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/jm3007799","volume":"55","author":"Verhoest P.R.","year":"2012","unstructured":"Verhoest P.R.; Fonseca K.R.; Hou X.; Proulx-Lafrance C.; Corman M.; Helal C.J.; Claffey M.M.; Tuttle J.B.; Coffman K.J.; Liu S.; Nelson F.; Kleiman R.J.; Menniti F.S.; Schmidt C.J.; Vanase-Frawley M.; Liras S.; Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J Med Chem 2012,55(21),9045-9054","journal-title":"J Med Chem"},{"key":"ref=131","unstructured":"Clinical trial study found in clinical trials for BI 409306:\n  NCT02281773  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02281773  (Accessed\n February 4, 2020)"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","volume":"139","author":"Xie Z.","year":"2006","unstructured":"Xie Z.; Adamowicz W.O.; Eldred W.D.; Jakowski A.B.; Kleiman R.J.; Morton D.G.; Stephenson D.T.; Strick C.A.; Williams R.D.; Menniti F.S.; Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 2006,139(2),597-607","journal-title":"Neuroscience"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nn.2153","volume":"11","author":"Bateup H.S.","year":"2008","unstructured":"Bateup H.S.; Svenningsson P.; Kuroiwa M.; Gong S.; Nishi A.; Heintz N.; Greengard P.; Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 2008,11(8),932-939","journal-title":"Nat Neurosci"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/jnc.13855","volume":"139","author":"Ooms M.","year":"2016","unstructured":"Ooms M.; Attili B.; Celen S.; Koole M.; Verbruggen A.; Van Laere K.; Bormans G.; [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. J Neurochem 2016,139(5),897-906","journal-title":"J Neurochem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1046\/j.1432-1327.1999.00963.x","volume":"266","author":"Fujishige K.","year":"1999","unstructured":"Fujishige K.; Kotera J.; Omori K.; Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur J Biochem 1999,266(3),1118-1127","journal-title":"Eur J Biochem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","volume":"28","author":"Nishi A.","year":"2008","unstructured":"Nishi A.; Kuroiwa M.; Miller D.B.; O\u2019Callaghan J.P.; Bateup H.S.; Shuto T.; Sotogaku N.; Fukuda T.; Heintz N.; Greengard P.; Snyder G.L.; Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum. J Neurosci 2008,28(42),10460-10471","journal-title":"J Neurosci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1076\/jhin.11.3.265.10391","volume":"11","author":"Baumeister A.A.","year":"2002","unstructured":"Baumeister A.A.; Francis J.L.; Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 2002,11(3),265-277","journal-title":"J Hist Neurosci"},{"key":"ref=138","first-page":"259","volume":"10","author":"Hollman A.","year":"2005","unstructured":"Hollman A.; Bank S.; Pett C.H.; Plants and the heart windfalls from the opium poppy: the discovery of papaverine and verapamil. Dialogues Cardiovasc Med 2005,10,259-263","journal-title":"Dialogues Cardiovasc Med"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","volume":"21","author":"Rodefer J.S.","year":"2005","unstructured":"Rodefer J.S.; Murphy E.R.; Baxter M.G.; PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005,21(4),1070-1076","journal-title":"Eur J Neurosci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2174\/0929867325666180309110629","volume":"25","author":"Zagorska A.","year":"2018","unstructured":"Zagorska A.; Partyka A.; Bucki A.; Gawalskax A.; Czopek A.; Pawlowski M.; Phosphodiesterase 10 inhibitors - novel perspectives for psychiatric and neurodegenerative drug discovery. Curr Med Chem 2018,25(29),3455-3481","journal-title":"Curr Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1038\/npp.2016.20","volume":"41","author":"Suzuki K.","year":"2016","unstructured":"Suzuki K.; Harada A.; Suzuki H.; Miyamoto M.; Kimura H.; TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms. Neuropsychopharmacology 2016,41(9),2252-2262","journal-title":"Neuropsychopharmacology"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/S0920-9964(12)70783-1","volume":"136","author":"DeMartinis N.","year":"2012","unstructured":"DeMartinis N.; Banerjee A.; Kumar V.; Boyer S.; Schmidt C.; Arroyo S.; Results of a phase 2a proof-of-concept trial with a PDE10A Inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophr Res 2012,136,S262","journal-title":"Schizophr Res"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1124\/jpet.115.230482","volume":"356","author":"Shiraishi E.","year":"2016","unstructured":"Shiraishi E.; Suzuki K.; Harada A.; Suzuki N.; Kimura H.; The phosphodiesterase 10a selective inhibitor tak-063 improves cognitive functions associated with schizophrenia in rodent models. J Pharmacol Exp Ther 2016,356(3),587-595","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.schres.2018.08.028","volume":"204","author":"Macek T.A.","year":"2019","unstructured":"Macek T.A.; McCue M.; Dong X.; Hanson E.; Goldsmith P.; Affinito J.; Mahableshwarkar A.R.; A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res 2019,204,289-294","journal-title":"Schizophr Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.1021\/jm5013648","volume":"57","author":"Kunitomo J.","year":"2014","unstructured":"Kunitomo J.; Yoshikawa M.; Fushimi M.; Kawada A.; Quinn J.F.; Oki H.; Kokubo H.; Kondo M.; Nakashima K.; Kamiguchi N.; Suzuki K.; Kimura H.; Taniguchi T.; Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. J Med Chem 2014,57(22),9627-9643","journal-title":"J Med Chem"},{"key":"ref=146","unstructured":"Schizophrenia.comOmeros Reports Positive Results from New\n Medication Phase 2 Clinical Trial for Schizophrenia. 2014.\n Available from: \n           xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/schizophrenia.com\/?p=40\">http:\/\/schizophrenia.com\/?p=40 (Accessed October\n 31, 2019)"},{"key":"ref=147","unstructured":"Clinical trial study found in clinical trials for OMS643762:\n NCT01952132.   xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01952132 (Accessed October 31, 2019)."},{"key":"ref=148","unstructured":"Clinical trial study found in clinical trials for EVP-6308 NCT02037074 xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02037074 (Accessed October 31, 2019)"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/jcdd5020022","volume":"5","author":"Chen S.","year":"2018","unstructured":"Chen S.; Knight W.E.; Yan C.; Roles of PDE1 in pathological cardiac remodeling and dysfunction. J Cardiovasc Dev Dis 2018,5(2),22","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"Cardinale A.","year":"2018","unstructured":"Cardinale A.; Fusco F.R.; Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther 2018,24(4),319-328","journal-title":"CNS Neurosci Ther"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1161\/CIRCULATIONAHA.117.030490","volume":"138","author":"Hashimoto T.","year":"2018","unstructured":"Hashimoto T.; Kim G.E.; Tunin R.S.; Adesiyun T.; Hsu S.; Nakagawa R.; Zhu G.; O\u2019Brien J.J.; Hendrick J.P.; Davis R.E.; Yao W.; Beard D.; Hoxie H.R.; Wennogle L.P.; Lee D.I.; Kass D.A.; Acute enhancement of cardiac function by phosphodiesterase type 1 inhibition: translational study in the dog and rabbit. Circulation 2018,138(18),1974-1987","journal-title":"Circulation"},{"key":"ref=152","unstructured":"Clinical trial study found in clinical trials for ITI-214:\n NCT03257046.  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03257046 (Accessed April 24, 2020)"},{"key":"ref=153","unstructured":"Clinical trial study found in clinical trials for ITI-214:\n NCT03387215  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03387215 (Accessed April 24, 2020)."},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2174\/1381612820666140826115245","volume":"21","author":"Zhang C.","year":"2015","unstructured":"Zhang C.; Yu Y.; Ruan L.; Wang C.; Pan J.; Klabnik J.; Lueptow L.; Zhang H-T.; O\u2019Donnell J.M.; Xu Y.; The roles of phosphodiesterase 2 in the central nervous and peripheral systems. Curr Pharm Des 2015,21(3),274-290","journal-title":"Curr Pharm Des"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","volume":"26","author":"Prickaerts J.","year":"2017","unstructured":"Prickaerts J.; Heckman P.R.A.; Blokland A.; Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs 2017,26(9),1033-1048","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=156","unstructured":"Clinical trial study found in clinical trials for PF-05180999:\n NCT01981486  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01981486 (Accessed April 26, 2020)"},{"key":"ref=157","unstructured":"Clinical trial study found in clinical trials for PF-05180999:\n NCT01981499  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01981499 (Accessed April 26, 2020)"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2009.09.007","volume":"35","author":"Houslay M.D.","year":"2010","unstructured":"Houslay M.D.; Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010,35(2),91-100","journal-title":"Trends Biochem Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fphar.2020.00259","volume":"11","author":"Phillips J.E.","year":"2020","unstructured":"Phillips J.E.; Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for inflammatory respiratory diseases. Front Pharmacol 2020,11,259","journal-title":"Front Pharmacol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-017-0709-1","volume":"77","author":"Keating G.M.","year":"2017","unstructured":"Keating G.M.; Apremilast: a review in psoriasis and psoriatic arthritis. Drugs 2017,77(4),459-472","journal-title":"Drugs"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"10304","DOI":"10.1021\/jm500836h","volume":"57","author":"Shao Y.X.","year":"2014","unstructured":"Shao Y.X.; Huang M.; Cui W.; Feng L-J.; Wu Y.; Cai Y.; Li Z.; Zhu X.; Liu P.; Wan Y.; Ke H.; Luo H.B.; Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent. J Med Chem 2014,57(24),10304-10313","journal-title":"J Med Chem"},{"key":"ref=162","unstructured":"Clinical trial study found in clinical trials for PF-04447943:\n NCT00930059  xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/www.clinicaltrials.gov\/ct2\/show\/ NCT00930059 (Accessed April 26, 2020)"},{"key":"ref=163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013417","volume":"5","author":"Giamp\u00e0 C.","year":"2010","unstructured":"Giamp\u00e0 C.; Laurenti D.; Anzilotti S.; Bernardi G.; Menniti F.S.; Fusco F.R.; Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease. PLoS One 2010,5(10)","journal-title":"PLoS One"},{"key":"ref=164","unstructured":"Clinical trial study found in clinical trials for Pf-02545920 NCT02342548 xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" https:\/\/www.clinicaltrials.gov\/ct2\/show\/ NCT02342548 (Accessed April 26, 2020)"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"796","DOI":"10.15252\/emmm.201506085","volume":"8","author":"Hankir M.K.","year":"2016","unstructured":"Hankir M.K.; Kranz M.; Gnad T.; Weiner J.; Wagner S.; Deuther-Conrad W.; Bronisch F.; Steinhoff K.; Luthardt J.; Kl\u00f6ting N.; Hesse S.; Seibyl J.P.; Sabri O.; Heiker J.T.; Bl\u00fcher M.; Pfeifer A.; Brust P.; Fenske W.K.; A novel thermoregulatory role for PDE10A in mouse and human adipocytes. EMBO Mol Med 2016,8(7),796-812","journal-title":"EMBO Mol Med"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/182764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/182764\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/182764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T12:24:21Z","timestamp":1619180661000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/182764\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":165,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,11,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200613202641","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}